NCT00124436 is a Phase 3 clinical trial of alitretinoin in Hand Dermatoses, sponsored by Basilea Pharmaceutica.

Who is sponsoring NCT00124436?

NCT00124436 is sponsored by Basilea Pharmaceutica.

What drugs are being tested in NCT00124436?

Interventions in NCT00124436: alitretinoin.

What condition does NCT00124436 study?

NCT00124436 studies Hand Dermatoses.

Is NCT00124436 still recruiting?

NCT00124436 is currently completed. Last updated 9 May 2023.

Last reviewed 2023-05-09 · How we verify

NCT00124436

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Follow up Efficacy and Safety Study of BAL4979 in the Treatment of Chronic Hand Dermatitis Refractory to Topical Treatment

Completed Phase 3 Last updated 9 May 2023

What this trial tests

Phase 3 trial testing alitretinoin in Hand Dermatoses in 300 participants. Completed in 1 February 2007.

Timeline

1 March 2005

Primary endpoint
1 January 2007

1 February 2007

Quick facts

Lead sponsor	Basilea Pharmaceutica
Phase	Phase 3
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	double
Primary purpose	other
Enrollment	300
Start date	1 March 2005
Primary completion	1 January 2007
Estimated completion	1 February 2007
Sites	1 location across Germany

Drugs / interventions tested

alitretinoin (ALITRETINOIN) — full drug profile →

Conditions studied

Hand Dermatoses — all drugs for Hand Dermatoses →

Sponsor

Basilea Pharmaceutica — full company profile →

Who can join

Adults 18 to 75, any sex, with Hand Dermatoses. Patients with the condition only — healthy volunteers not accepted.

What's being measured

Primary outcomes are the specific endpoints the trial is designed to prove or disprove.

Response of chronic hand dermatitis to study treatment as assessed by Physicians Global Assessment, at week 12 or 24

Sponsor's own description

Patients who have been treated in study protocol BAP089 may have responded to treatment, and subsequently relapsed to \>75% of the baseline disease severity, will be investigated for response to further treatment with alitretinoin. Also, patients who have responded with mild or moderate disease will be investigated for additional treatment effect after prolongated treatment.

Publications & conference data

2 peer-reviewed publications reference this trial (live from Europe PMC):

Interventions for hand eczema.
Christoffers WA, Coenraads PJ, Svensson Å, Diepgen TL, et al · · 2019 · cited 37× · PMID 31025714 · DOI 10.1002/14651858.cd004055.pub2
Use of Longitudinal Dose-Response Modeling to Support the Efficacy and Tolerability of Alitretinoin in Severe Refractory Chronic Hand Eczema (CHE).
Schmith GD, Singh R, Gomeni R, Graff O, et al · · 2015 · cited 4× · PMID 26225249 · DOI 10.1002/psp4.24

Verify or expand the search:

Other trials of alitretinoin

Trials testing the same drug.

NCT01245140 — Efficacy of Alitretinoin Treatment in Patients With Pustular Form of Psoriasis · Phase 2 · completed
NCT00817063 — Efficacy and Safety of a Retinoid in the Treatment of Severe Chronic Hand Eczema · Phase 3 · completed

Other Basilea Pharmaceutica trials

Trials by the same sponsor.

NCT06961708 — A Study of Fosmanogepix in Healthy Adult Chinese Subjects · Phase 1 · completed
NCT06808646 — A Study to Assess the Effect of Ceftobiprole on the PK of Pitavastatin and on Plasma Levels of Coproporphyrin · Phase 1 · completed
NCT06733675 — Safety and PK of Ceftibuten-ledaborbactam Etzadroxil Fixed-dose Combination · Phase 1 · recruiting
NCT05421858 — A Phase 3 Efficacy and Safety Study of Fosmanogepix for the Treatment of Adult Participants With Candidemia and/or Invas · Phase 3 · recruiting
NCT06665555 — Plasma and Intrapulmonary Pharmacokinetics of Ceftibuten and Ledaborbactam in Healthy Male and Female Participants 18 to · Phase 1 · completed

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT00124436 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Basilea Pharmaceutica
Last refreshed: 9 May 2023

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT00124436.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing